Top

Published in:

01-12-2018 | Editorial

Fabula (non) acta est….Endocrine

Published in: Endocrine | Issue 3/2018

Svetonio Vite dei Cesari Aug. II, 97–99.

A. Giustina, Quo vadis Endocrine. Endocrine 39, 101–103 (2011). https://doi.org/10.1007/s12020-11-9448-

A. Giustina A., J.D. Veldhuis, Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human. Endocr. Rev. 19(6), 717–797 (1998).PubMed

A. Coppola, L. Sasso, A. Bagnasco, A. Giustina, C. Gazzaruso, The role of patient education in the prevention and management of type 2 diabetes: an overview. Endocrine 53(1), 18–27 (2016). https://doi.org/10.1007/s12020-015-0775-7 CrossRefPubMed

A. Pascale, N. Marchesi, C. Marelli, A. Coppola, L. Luzi, S. Govoni, A. Giustina, C. Gazzaruso, Microbiota and metabolic diseases. Endocrine 61(3), 357–371 (2018). https://doi.org/10.1007/s12020-018-1605-5 CrossRefPubMed

S. Frara, S. Chiloiro, T. Porcelli, A. Giampietro, G. Mazziotti, L. De Marinis, A. Giustina, Bone safety of dual-release hydrocortisone in patients with hypopituitarism. Endocrine 60(3), 528–531 (2018). https://doi.org/10.1007/s12020-017-1512-1 CrossRefPubMed

G. Tulipano, L. Faggi, S. Schulz, M. Spinello, A. Giustina, Effects of pasireotide (SOM230) on protein turnover and p70S6 kinase-S6 ribosomal protein signaling pathway in rat skeletal muscle cells. Endocrine 57(1), 179–182 (2017). https://doi.org/10.1007/s12020-017-1235-3 CrossRefPubMed

A. Giustina, Optimal use of pegvisomant in acromegaly: are we getting there? Endocrine 48(1), 3–8 (2015). https://doi.org/10.1007/s12020-014-0462-0 CrossRefPubMed

M. Gola, A. Giustina, Growth hormone deficiency and cardiovascular risk: do we need additional markers? Endocrine 42(2), 240–242 (2012)CrossRef

10.

P. Mortini, L.R. Barzaghi, L. Albano, P. Panni, M. Losa, Microsurgical therapy of pituitary adenomas. Endocrine 59(1), 72–81 (2018). https://doi.org/10.1007/s12020-017-1458-3 CrossRefPubMed

11.

S. Filetti, P.W. Ladenson, M. Biffoni, M.G. D’Ambrosio, L. Giacomelli, S. Lopatriello, The true cost of thyroid surgery determined by a micro-costing approach. Endocrine 55(2), 519–529 (2017). https://doi.org/10.1007/s12020-016-0980-z CrossRefPubMed

Title: Fabula (non) acta est….Endocrine
Publication date: 01-12-2018
Published in: Endocrine / Issue 3/2018
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI: https://doi.org/10.1007/s12020-018-1790-2

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Fabula (non) acta est….Endocrine

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Please log in to get access to this content

Other articles of this Issue 3/2018

Autoimmune pituitary involvement in Prader–Willi syndrome: new perspective for further research

The effects of metformin on simple obesity: a meta-analysis

Tumoral MGMT content predicts survival in patients with aggressive pituitary tumors and pituitary carcinomas given treatment with temozolomide

SSTR2A expression in medullary thyroid carcinoma is correlated with longer survival

Safety and efficiency of ultrasound-guided low power microwave ablation in the treatment of cervical metastatic lymph node from papillary thyroid carcinoma: a mean of 32 months follow-up study

Cushing’s syndrome: comparison between Cushing’s disease and adrenal Cushing’s

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page